Download PDFPDF

Efficacy of TNF α blockade in cyclophosphamide resistant neuro-Behçet disease
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Further evidence for the value of TNFα blockade in neuro Behçets disease
    • Jane E Alty, Specialist Registrar in Neurology
    • Other Contributors:
      • Tanya Monaghan, John M. Bamford.

    Dear Editor,

    Ribi et al.[1] describe an interesting case of neuro Behçets disease (NB) being successfully treated with the tumour necrosis factor alpha (TNFα) monoclonal antibody infliximab. We report using the soluble recombinant human TNFα receptor protein, etanercept in a patient with longstanding NB. To the best of our knowledge there are no previous clinical reports on the use of etanercept in NB.


    Show More
    Conflict of Interest:
    None declared.